Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by woundedkneeon May 14, 2021 6:06am
177 Views
Post# 33201726

RE:RE:Share price taken down

RE:RE:Share price taken downDownward trends occur with every stock. There isn't a stock in history that has not experienced a downward trend at one time or another. All I said was that I believed this trend was not normal because of the low volume and it was just an opinion. This could also be attributed to the old saying "sell in May and go away", who knows.
It's very clear to me why there are very few buyers right now and that is that the catalysts that will drive this sp north are still several weeks or months away.
Let's see what the price targets become and how many more analysts jump on board after we are into Phase 3 trials or going further, if we succeed with those trials.
Buyers such as myself, who are in this at a higher price, have of course two obvious choices and that is to sell, perhaps with the intention of buying later, or stay confident, knowing this will eventually turn around.
StockingUp21, your points are well taken. Can you tell us what the lower price target is. I have not read them, but I bet it is still much higher than yesterday's close. gl
<< Previous
Bullboard Posts
Next >>